title: Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis.
abstract: For solid organ transplant (SOT) donors, nucleic acid-amplification testing (NAT) may reduce human immunodeficiency virus (HIV) and hepatitis C virus (HCV) transmission over antibody (Ab) testing given its shorter detection window period. We compared SOT donor NAT + Ab versus Ab alone using decision models to estimate incremental cost-effectiveness ratios (ICERs; cost per quality-adjusted life year [QALY] gained) from the societal perspective across a range of HIV/HCV prevalence values and NAT costs. The cost per QALY gained was calculated for two scenarios: (1) favorable: low cost ($150/donor)/high prevalence (HIV: 1.5%; HCV: 18.2%) and (2) unfavorable: high cost ($500/donor)/low prevalence (HIV: 0.1%; HCV: 1.5%). In the favorable scenario, adding NAT screening cost $161 013 per QALY gained for HIV was less costly) for HCV, and cost $86 653 per QALY gained for HIV/HCV combined. For the unfavorable scenario, the costs were $15 568 484, $221 006 and $10 077 599 per QALY gained, respectively. Universal HCV NAT + Ab for donors appears cost-effective to reduce infection transmission from SOT donors, while HIV NAT + Ab is not, except where HIV NAT is ≤$150/donor and prevalence is ≥1.5%. Our analyses provide important data to facilitate the decision to implement HIV and HCV NAT for deceased SOT donors and shape national policy regarding how to reduce infection transmission in SOT.
authors.affiliation: Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, CA.
authors.forename: J C
authors.initials: JC
authors.lastname: Lai
authors.forename: J G
authors.initials: JG
authors.lastname: Kahn
authors.forename: M
authors.initials: M
authors.lastname: Tavakol
authors.forename: M G
authors.initials: MG
authors.lastname: Peters
authors.forename: J P
authors.initials: JP
authors.lastname: Roberts
mesh_terms: D001782:Blood Donors; D003362:Cost-Benefit Analysis; D004279:DNA, Viral / Q000235:genetics; D003657:Decision Making; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000175:diagnosis* / Q000191:economics / Q000517:prevention & control / Q000635:transmission; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis* / Q000191:economics / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D008403:Mass Screening / Q000191:economics*; D018803:Models, Economic; D021141:Nucleic Acid Amplification Techniques / Q000191:economics*; D016377:Organ Transplantation; D011379:Prognosis
chemical_list: D004279:DNA, Viral
keywords: Cost-effectiveness analysis; graft; organ transplantation; surgery
references.citation: Nephrol Dial Transplant. 2010 Sep;25(9):3106-15
references.pmid: 20228071
references.citation: Transplantation. 2010 Dec 15;90(11):1165-71
references.pmid: 20861806
references.citation: Arch Intern Med. 2004 Nov 22;164(21):2377-82
references.pmid: 15557419
references.citation: Liver Transpl. 2011 Nov;17(11):1333-43
references.pmid: 21770017
references.citation: Am J Gastroenterol. 2003 Mar;98(3):630-8
references.pmid: 12650799
references.citation: Am J Transplant. 2009 Mar;9(3):620-8
references.pmid: 19191766
references.citation: Med Decis Making. 2002 Nov-Dec;22(6):475-81
references.pmid: 12458977
references.citation: J Clin Microbiol. 2002 Jul;40(7):2408-19
references.pmid: 12089255
references.citation: Am J Transplant. 2009 Aug;9(8):1929-35
references.pmid: 19538493
references.citation: Crit Care Med. 2012 Oct;40(10):2773-80
references.pmid: 22846779
references.citation: Transplantation. 2004 Dec 27;78(12):1704-10
references.pmid: 15614139
references.citation: Transfusion. 2005 Dec;45(12):1853-63
references.pmid: 16371038
references.citation: Am J Transplant. 2010 Apr;10(4 Pt 2):1003-19
references.pmid: 20420649
references.citation: Health Policy. 2008 Apr;86(1):85-96
references.pmid: 17996975
references.citation: Am J Transplant. 2010 Apr;10(4):889-899
references.pmid: 20121734
references.citation: Public Health Rep. 2013 Jul;128(4):247-343
references.pmid: 23814319
references.citation: AIDS Rev. 2012 Jul-Sep;14(3):195-207
references.pmid: 22833063
references.citation: Am J Transplant. 2007 Dec;7(12):2723-6
references.pmid: 17983391
references.citation: Am J Transplant. 2011 Jun;11(6):1201-8
references.pmid: 21645253
references.citation: Vox Sang. 2004 Jan;86(1):28-40
references.pmid: 14984557
references.citation: Hepatology. 2013 Jun;57(6):2164-70
references.pmid: 23280550
references.citation: J Infect Dis. 2003 Nov 15;188(10):1412-20
references.pmid: 14624365
references.citation: AIDS. 1988 Feb;2(1):51-4
references.pmid: 3128997
references.citation: Am J Transplant. 2011 Jun;11(6):1176-87
references.pmid: 21366859
references.citation: Transfusion. 2011 Feb;51(2):421-9
references.pmid: 20849409
references.citation: Sex Transm Dis. 2013 Mar;40(3):197-201
references.pmid: 23403600
references.citation: Ann Intern Med. 1990 Nov 15;113(10):733-9
references.pmid: 2240875
references.citation: Hepatology. 1999 Apr;29(4):1220-6
references.pmid: 10094968
references.citation: J Hepatol. 2004 Nov;41(5):830-6
references.pmid: 15519657
references.citation: Am J Transplant. 2011 Jun;11(6):1188-200
references.pmid: 21401874
references.citation: Transfusion. 2003 Jun;43(6):721-9
references.pmid: 12757522
references.citation: Med Decis Making. 2000 Jul-Sep;20(3):332-42
references.pmid: 10929856
references.citation: Liver Transpl. 2012 Jun;18(6):716-26
references.pmid: 22328294
references.citation: Transfusion. 2003 Jun;43(6):788-98
references.pmid: 12757531
references.citation: Value Health. 2008 Dec;11(7):1144-53
references.pmid: 18494750